GPC3 and hepatocellular carcinoma: Especially GPC3 has been studied with regards to therapies of HCC where the recombinant fully humanized monoclonal antibody GC33 has shown good tolerance in phase I and II trials (Zhu et al. 2013; Ikeda et al. 2014).